Inverness/Biosite merger gets US OK:
This article was originally published in Clinica
Inverness Medical Innovations' pending acquisition of San Diego, California-based diagnostics company Biosite has received the go-ahead from US antitrust authorities. The proposed transaction went through the 30-day waiting period required under the US Hart-Scott-Rodino Act without the company having to address any potential anti-competition concerns. Inverness' tender offer for Biosite shares, at $92.50 per share, is currently underway and scheduled to expire at midnight on June 25.